ClinicalTrials.gg
CompletedNCT00257205Updated Jul 2, 2012

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

A Phase 3 interventional study of dacarbazine and CP-675,206 in Melanoma, sponsored by AstraZeneca. Completed at 144 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-02.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
655
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tremelimumab in Melanoma — none open to participants now, none under way, none of them phase 3. tremelimumab · Melanoma.

Enrollment
Largest of 12
655 · median 51
Started
2006
with 2 others
Phase 3
Only one
of the 12
Registered
3rd of 12
by date
Lead sponsor
6 of 12
AstraZeneca

Among the 12 studies testing tremelimumab in Melanoma, this one has the largest enrollment, is one of 3 that started in 2006, is the only one in phase 3, and was the 3rd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 12 studies testing tremelimumab in Melanoma is open now. The open studies under Melanoma, anywhere →

About tremelimumab

tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing tremelimumab in Melanoma as a file.
02

Study summary

This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Surgically incurable melanoma, either Stage IV or IIIC with N3 status for regional lymph nodes and in-transit or satellite lesions.
  • Serum lactic acid dehydrogenase (LDH) \<= 2 x
  • performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Received any systemic therapy for melanoma except post-surgical treatment with cytokines (eg, alpha-interferon or GM-CSF) or with vaccines after complete resection of melanoma.
  • History of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
655 participants (actual)

Study arms

  • Active comparator
    B

    Choice of one or the other Dacarbazine or Temozolomide(CP-675,206) (choice)

    Drug: dacarbazine · Drug: temozolomide

  • Experimental
    A

    Drug: CP-675,206

Interventions

  • decarbazine 1000 mg/m2 IV Q 21 days x 12

  • CP-675,206 15 mg/kg IV Q 90 days x 4

    Also known as: anti-CTLA4 human monoclonal antibody

  • temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12

06

What researchers measure

Primary outcomes

  1. overall survival

    Time frame: August 2010

Secondary outcomes

  1. adverse events

    Time frame: 1 year

  2. PFS at 6 months

    Time frame: 6 months

  3. objective tumor response

    Time frame: 1 year

  4. Durable response

    Time frame: 6 months

  5. pharmacokinetics endpoints

    Time frame: 15 months

  6. pharmacogenomic endpoints

    Time frame: 1 year

  7. HQol

    Time frame: 1 year

  8. healthcare resource utilization and loss of productivity

    Time frame: 1 year

  9. human antihuman antibody response for patients in Arm A

    Time frame: 15 months

07

Study locations

144 sites
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Mobile, Alabama 36607, United States
  • Research Site
    Scottsdale, Arizona 85260, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Bakersfield, California 93309, United States
  • Research Site
    Corona, California 92879, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    Glendora, California 91741, United States
  • Research Site
    Huntington Beach, California 92648, United States
  • Research Site
    Long Beach, California 90813, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    Los Angeles, California 90095-6970, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Oxnard, California 93030, United States
  • Research Site
    Pasadena, California 91105, United States
  • Research Site
    Pomona, California 91767, United States
  • Research Site
    Rancho Cucamonga, California 91730, United States
  • Research Site
    Santa Barbara, California 93105, United States
  • Research Site
    Santa Maria, California 93454, United States
  • Research Site
    West Covina, California 91790, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Stamford, Connecticut 06902-3628, United States
  • Research Site
    Boynton Beach, Florida 33426, United States
  • Research Site
    Lake Worth, Florida 33461-4710, United States
  • Research Site
    Zion, Illinois 60099, United States
  • Research Site
    Beech Grove, Indiana 46107, United States
  • Research Site
    Indianapolis, Indiana 46237, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Baltimore, Maryland 21237-3998, United States
  • Research Site
    Creve Coeur, Missouri 63141, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    St. Louis, Missouri 63110, United States
  • Research Site
    St. Peters, Missouri 63376, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Henderson, Nevada 89015, United States
  • Research Site
    Henderson, Nevada 89052, United States
  • Research Site
    Las Vegas, Nevada 89109, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Las Vegas, Nevada 89135, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    Morristown, New Jersey 07962, United States
  • Research Site
    Albany, New York 12206, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Chapel Hill, North Carolina 27599-7600, United States
  • Research Site
    Charlotte, North Carolina 28203, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Canton, Ohio 44718, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Dover, Ohio 44718, United States
  • Research Site
    Bethlehem, Pennsylvania 18015, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Federal Way, Washington 98003, United States
  • Research Site
    Lakewood, Washington 98499, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Ciudad de Buenos Aires, Buenos Aires C1280AEA, Argentina
  • Research Site
    Waratah, New South Wales 2300, Australia
  • Research Site
    Westmead, New South Wales 2145, Australia
  • Research Site
    Woolloongabba, Queensland 4102, Australia
  • Research Site
    Adelaide, South Australia 5000, Australia
  • Research Site
    Launceston, Tasmania 7250, Australia
  • Research Site
    East Melbourne, Victoria 3002, Australia
  • Research Site
    Wien, A-1090, Austria
  • Research Site
    Brussel, 1090, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Turnhout, 2300, Belgium
  • Research Site
    Wilrijk, 2610, Belgium
  • Research Site
    Yvoir, 5530, Belgium
  • Research Site
    Calgary, Alberta T2N 4N2, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Victoria, British Columbia V8R 6V5, Canada
  • Research Site
    Winnipeg, Manitoba R3E 0V9, Canada
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    London, Ontario N6A 4L6, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Windsor, Ontario N8W 1L9, Canada
  • Research Site
    Windsor, Ontario N8W 2X3, Canada
  • Research Site
    Montreal, Quebec H2L 4M1, Canada
  • Research Site
    Quebec, G1R 2J6, Canada
  • Research Site
    Montpellier, Cedex 05 34280, France
  • Research Site
    Besancon, 25030, France
  • Research Site
    Bordeaux, 33075, France
  • Research Site
    Boulogne, 92104, France
  • Research Site
    Caen, 14033, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Marseille, 13009, France
  • Research Site
    Nantes Cedex 1, 44035, France
  • Research Site
    Paris, 75010, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Frankfurt, 60488, Germany
  • Research Site
    Hannover, 30449, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    Tuebingen, 72076, Germany
  • Research Site
    Athens, 115 27, Greece
  • Research Site
    Jerusalem, 91120, Israel

Showing the first 100 of 144 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Friedlander P, Wood K, Wassmann K, Christenfeld AM, Bhardwaj N, Oh WK. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. J Immunother Cancer. 2018 Sep 18;6(1):90. doi: 10.1186/s40425-018-0408-9. PubMed 30227886 ↗
  • Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7. PubMed 23295794 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2005
First posted
Nov 22, 2005
Start
Mar 2006
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Results delay requested
Jan 3, 2011
Last update
Jul 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00257205
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 22, 2005
Start date
Mar 2006
Primary completion
Aug 2010
Completion
Aug 2010
Last update
Jul 2, 2012

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tremelimumab

Start the discussion